Point of View: What next for gain-of-function research in Europe?

  1. Robin Fears  Is a corresponding author
  2. Volker ter Meulen  Is a corresponding author
  1. European Academies Science Advisory Council, Germany
  2. German National Academy of Sciences Leopoldina, Germany


A working group on gain-of-function research set up by the European Academies Science Advisory Council (EASAC) has emphasised the importance of ensuring that the necessary safeguards and policies are in place

Main text

Infectious diseases continue to be responsible for a substantial proportion of deaths worldwide and there is evidence for a significant increase in the number of outbreaks over the past 30 years. Although some of this increase may be due to improved detection and reporting, animal diseases that can be transmitted to humans are among the major causes of human infection (Smith et al., 2014).

Influenza outbreaks are a particular concern: in the UK, for example, the potential impact of an influenza pandemic has been identified as the highest priority in the UK Government Risk Register for 2015. Our current inability to predict which specific virus subtypes will trigger the next influenza pandemic highlights the vital importance of addressing gaps in the knowledge base. Research on a wide range of topics—including the study of virus transmission, host range, drug resistance, infectivity, immunity and virulence—is urgently needed to fill these gaps. In this article we focus on the issues raised by proposals to use ‘gain-of-function’ experiments to fill some of these gaps. Such experiments have a long history of providing useful information in virology.

Gain-of-function experiments involve modifying a virus and analysing the link between modified genotype and phenotype. However, proposals to modify the H5N1 variant of the influenza virus in order to affect its transmission potential, and thereby understand the factors that determine the ability of an animal virus to spread to humans (and between humans) by the aerosol route, were controversial (Russell et al., 2014; Schultz-Cherry et al., 2014; Palu, 2014; Wain-Hobson, 2014), and there is still a de facto moratorium on such research in the US.

Self-regulation is a necessary first step for gain-of-function research, but this does not mean that each researcher is free to decide for themselves what procedures to follow.

Experiments are of concern if they have the potential to cause serious disease, and these concerns encompass biosafety (relating to the accidental release of a pathogen from containment), biosecurity (relating to intentional misuse; see NRC, 2004), and bioethics (the principles and their place in research review procedures). Although potentially dangerous research studies are already subject to stringent regulations in many countries, recent controversies prompted the European Academies Science Advisory Council (EASAC) to set up a working group to examine the issues raised by gain-of-function research and to make recommendations for the management of such research and its outputs in the EU. This working group contained the present authors and other scientists with a wide range of relevant experience. Here we discuss some of the recommendations made by the working group (see EASAC, 2015 for the full report).

Scientific responsibility and benefit-risk assessment

Self-regulation is a necessary first step for gain-of-function research, but this does not mean that each researcher is free to decide for themselves what procedures to follow. Everyone involved must conform to existing regulations, codes of conduct and established methods for biorisk management (see EASAC, 2015 for a list of existing regulations in Europe, and details of work by the World Health Organisation and the OECD in this area).

Moreover, proposals for gain-of-function studies—particularly those that intend to alter virus transmission, host range, drug resistance, infectivity, immunity and virulence—have to be justified by their authors to a wide range of bodies (the institutions where the work will be carried out, the agencies that will fund the work, the relevant ethics committees, and the relevant national authorities), as well as their peers, on a case-by-case basis. This process must involve a thorough analysis of the risks and benefits of the research being proposed. Researchers also need to demonstrate that the information they need can only be obtained from gain-of-function experiments.

A clear theme in both Europe and the US is the need for the scientific community to engage more broadly with the public, explaining the reasons for doing gain-of-function research.

There are many uncertainties in the data used to evaluate benefit and risk, and this can lead to controversy. It should also be acknowledged that potential benefits of research are sometimes overstated by scientists: however, it is also true that the benefits of research might only become clear much later. Views vary on whether benefit should be quantified in terms of future public health impact or described in terms of the generation of knowledge, and on the extent to which benefits may be lost if research is not allowed. There have been concerns that research that could help to streamline the production of vaccines might suffer if gain-of-function experiments are banned (Cohen, 2015; Ping et al., 2015). Because of the multiple challenges involved in assessing risk and benefit, the EASAC report concludes that any benefit-risk analysis cannot be regarded as a ‘once and for all’ calculation, and that all the relevant parties need to understand and communicate the issues on an on-going basis.

The EASAC report also recommends that there is no need for a new advisory body at the EU level. Rather, all EU Member States should have a clear national advisory mechanism on procedures for assessing and managing biosafety and biosecurity risks. In the UK, for example, the Health and Safety Executive has statutory powers, but other EU Member States have different mechanisms and not all have statutory powers. There is need to harmonise the implementation of good practice in these respects. All countries should also adopt a ‘layered’ approach with researchers, research institutions, research funders and national authorities all being responsible for the regulation of gain-of-function research. Such a layered approach at the country level will spread good practice, increase accountability, and help to improve public trust in research.

Researchers and institutions also have to recognise their responsibility to make decisions about publishing sensitive information and, together with funders, ethics committees and others, need to consider these issues throughout the research process, starting when the research is first proposed, rather than delaying the decision until a manuscript is ready for submission to a journal. The oversight within the scientific community must involve journals and professional societies, as well as researchers, their funders and institutions (and national advisory bodies in complex cases). Journal editors in the US recently came to a similar conclusion (Casadevall et al., 2015). Regarding the question of what to do when European researchers submit a manuscript to a journal that is not based in Europe, EASAC advises that the use of the EU’s export control regime is an inappropriate and ineffective vehicle to block such submissions.

Many of EASAC’s recommendations have been welcomed by the European Commission, who will now consider how to incorporate EASAC advice into guidance for Horizon 2020 research grant applicants and evaluators.

The EASAC report resonates with the themes that are emerging from discussions in the US involving the National Academies, the National Science Advisory Board for Biosecurity (NSABB) and the National Institutes of Health. A National Academies workshop in December 2014 observed that the challenges involved in regulating gain-of-function research were international, that attention should be focussed on those experiments of greatest concern, that researchers and their institutions must accept responsibility, and that analysing the risks and benefits is not straightforward. Since then, a quantitative risk-benefit analysis has been initiated (Casagrande et al., 2015), and the NSABB has set up a working group to look into the issues surrounding gain-of-function research (Kanabrocki, 2015). In its interim report the NASBB working group noted that the US already has a robust policy framework for the regulation of research, and any future policies should build on this framework.

Challenges for wider engagement

A clear theme in both Europe and the US is the need for the scientific community to engage more broadly with the public, explaining the reasons for doing gain-of-function research, discussing the potential risks and benefits of this research, and explaining the biorisk management practices adopted. Engagement with public interests can be considered at three levels. First, on the global scale, the scientific community has to ensure that the public health benefits that arise from innovation based on gain-of-function research are made available to everyone. Second, on the national level, scientists need to convince the public that taxpayer funds are being spent wisely. Third, on a local level, scientists must engage with those who live near research facilities to reassure them about safety.

Another clear theme is the need for the regulatory authorities, funding bodies and professional societies in different countries to work together to share expertise in the regulation of gain-of-function research and in risk-benefit analysis. Academies of science have a clear role to play at the national level, and international networks of academies can bring scientists from different countries together to study and make recommendations on specific issues: the working group on biosecurity set up by the InterAcademy Partnership is an example of this.

Influenza pandemics are currently unpredictable. However, we still need to be ready for the next pandemic, and that includes being in a position to perform gain-of-function research if that is the only way to obtain the information needed to deal with the pandemic. And, as should be clear from above, this means that many different stakeholders—scientists, institutions, funding agencies, ethics committees, national regulatory authorities, scientific societies and journals—need to work together to ensure that we are prepared.


Article and author information

Author details

  1. Robin Fears, Director of the Biosciences Programme

    European Academies Science Advisory Council, Halle, Germany
    For correspondence
    Competing interests
    The authors declare that no competing interests exist.
  2. Volker ter Meulen, Chair of the EASAC working group on gain of function

    German National Academy of Sciences Leopoldina, Halle, Germany
    For correspondence
    Competing interests
    The authors declare that no competing interests exist.


We thank all the members of the EASAC Working Group: Goran Hermeren (Sweden), Ursula Jenal (Switzerland), Hans Klenk (Germany), Andre Knottnerus (The Netherlands), Maria Masucci (Sweden), John McCauley (UK), Thomas Mettenleiter (Germany), Giorgio Palu (Italy), Gyorgy Posfai (Hungary), Bert Rima (Ireland), John Skehel (UK), and Simon Wain-Hobson (France).

Publication history

  1. Received: November 16, 2015
  2. Accepted: November 20, 2015
  3. Version of Record published: December 30, 2015 (version 1)


© 2015, Fears et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.


  • 1,613
  • 165
  • 2

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Robin Fears
  2. Volker ter Meulen
Point of View: What next for gain-of-function research in Europe?
eLife 4:e13035.
  1. Further reading

Further reading

    1. Microbiology and Infectious Disease
    Xufeng Xie, Xi Chen ... Yongguo Cao
    Research Article

    Leptospirosis is an emerging infectious disease caused by pathogenic Leptospira spp. Humans and some mammals can develop severe forms of leptospirosis accompanied by a dysregulated inflammatory response, which often results in death. The gut microbiota has been increasingly recognized as a vital element in systemic health. However, the precise role of the gut microbiota in severe leptospirosis is still unknown. Here, we aimed to explore the function and potential mechanisms of the gut microbiota in a hamster model of severe leptospirosis. Our study showed that leptospires were able to multiply in the intestine, cause pathological injury, and induce intestinal and systemic inflammatory responses. 16S rRNA gene sequencing analysis revealed that Leptospira infection changed the composition of the gut microbiota of hamsters with an expansion of Proteobacteria. In addition, gut barrier permeability was increased after infection, as reflected by a decrease in the expression of tight junctions. Translocated Proteobacteria were found in the intestinal epithelium of moribund hamsters, as determined by fluorescence in situ hybridization, with elevated lipopolysaccharide (LPS) levels in the serum. Moreover, gut microbiota depletion reduced the survival time, increased the leptospiral load, and promoted the expression of proinflammatory cytokines after Leptospira infection. Intriguingly, fecal filtration and serum from moribund hamsters both increased the transcription of TNF-α, IL-1β, IL-10, and TLR4 in macrophages compared with those from uninfected hamsters. These stimulating activities were inhibited by LPS neutralization using polymyxin B. Based on our findings, we identified an LPS neutralization therapy that significantly improved the survival rates in severe leptospirosis when used in combination with antibiotic therapy or polyclonal antibody therapy. In conclusion, our study not only uncovers the role of the gut microbiota in severe leptospirosis but also provides a therapeutic strategy for severe leptospirosis.

    1. Microbiology and Infectious Disease
    2. Structural Biology and Molecular Biophysics
    Siena J Glenn, Zealon Gentry-Lear ... Arden Baylink
    Research Article

    Bacteria of the family Enterobacteriaceae are associated with gastrointestinal (GI) bleeding and bacteremia and are a leading cause of death, from sepsis, for individuals with inflammatory bowel diseases. The bacterial behaviors and mechanisms underlying why these bacteria are prone to bloodstream entry remain poorly understood. Herein, we report that clinical isolates of non-typhoidal Salmonella enterica serovars, Escherichia coli, and Citrobacter koseri are rapidly attracted toward sources of human serum. To simulate GI bleeding, we utilized an injection-based microfluidics device and found that femtoliter volumes of human serum are sufficient to induce bacterial attraction to the serum source. This response is orchestrated through chemotaxis and the chemoattractant L-serine, an amino acid abundant in serum that is recognized through direct binding by the chemoreceptor Tsr. We report the first crystal structures of Salmonella Typhimurium Tsr in complex with L-serine and identify a conserved amino acid recognition motif for L-serine shared among Tsr orthologues. We find Tsr to be widely conserved among Enterobacteriaceae and numerous World Health Organization priority pathogens associated with bloodstream infections. Lastly, we find that Enterobacteriaceae use human serum as a source of nutrients for growth and that chemotaxis and the chemoreceptor Tsr provide a competitive advantage for migration into enterohemorrhagic lesions. We define this bacterial behavior of taxis toward serum, colonization of hemorrhagic lesions, and the consumption of serum nutrients as ‘bacterial vampirism’, which may relate to the proclivity of Enterobacteriaceae for bloodstream infections.